疟疾
诊断试验
现存分类群
全球卫生
检测点注意事项
疾病
疾病负担
医疗保健
疟疾的诊断
疾病负担
传染病(医学专业)
有限的资源
医学
业务
重症监护医学
风险分析(工程)
经济增长
病理
经济
生物
兽医学
进化生物学
恶性疟原虫
作者
Eric L. Miller,Hadley D. Sikes
摘要
Immunochromatographic rapid diagnostic tests (RDTs) have demonstrated significant potential for use as point-of-care diagnostic tests in resource-limited settings. Most notably, RDTs for malaria have reached an unparalleled level of technological maturity and market penetration, and are now considered an important complement to standard microscopic methods of malaria diagnosis. However, the technical development of RDTs for other infectious diseases, and their uptake within the global health community as a core diagnostic modality, has been hindered by a number of extant challenges. These range from technical and biological issues, such as the need for better affinity agents and biomarkers of disease, to social, infrastructural, regulatory and economic barriers, which have all served to slow their adoption and diminish their impact. In order for the immunochromatographic RDT format to be successfully adapted to other disease targets, to see widespread distribution, and to improve clinical outcomes for patients on a global scale, these challenges must be identified and addressed, and the global health community must be engaged in championing the broader use of RDTs.
科研通智能强力驱动
Strongly Powered by AbleSci AI